Following last ER, I was impressed by BNTX capacity to flex its costs i.e business model (notably vs MRNA) to keep being profitable. Now 17 Bil. in cash. Also believe it was conservative on its modified 2023 guidance compared with PFE ( one is wrong imo). So i believe it is still a cheap stock trading around 30 net of cash (back to before Covid). It filled the small gap (orange box). I expect it to test 125 again. Then it will be up to the cancer treatment narrative.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。